Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00063999 · FLOW

Participant flow

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer · Source last updated 2021-10-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive doxorubicin IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Doxorubicin, Cisplatin, Paclitaxel
  2. description
    Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
    id
    FG001
    title
    Paclitaxel, Carboplatin
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        44
      2. group Id
        FG001
        num Subjects
        24
      type
      Ineligible
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        692
      2. group Id
        FG001
        num Subjects
        689
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        647
      2. group Id
        FG001
        num Subjects
        665
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        45
      2. group Id
        FG001
        num Subjects
        24
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
GOG 0209 accrued 1381 patients from August 2003 to April 2009. 1312 of these patients were eligible.
Complete source fields
groups
  1. description
    Patients receive doxorubicin IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Doxorubicin, Cisplatin, Paclitaxel
  2. description
    Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
    id
    FG001
    title
    Paclitaxel, Carboplatin
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        44
      2. group Id
        FG001
        num Subjects
        24
      type
      Ineligible
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        692
      2. group Id
        FG001
        num Subjects
        689
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        647
      2. group Id
        FG001
        num Subjects
        665
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        45
      2. group Id
        FG001
        num Subjects
        24
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
GOG 0209 accrued 1381 patients from August 2003 to April 2009. 1312 of these patients were eligible.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice